Arformoterol Tartrate is indicated for long-term maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. It is administered twice daily (morning and evening).

Important limitation of use: Arformoterol nebulizer solution is not intended for the relief of acute worsening of COPD symptoms. Use of long-acting beta-2 agonists (LABAs), including Arformoterol, in asthma patients may increase the risk of asthma-related death.

Arformoterol tartrate is the (R,R)-enantiomer of formoterol and functions as a selective beta-2 adrenergic bronchodilator. It demonstrates greater potency compared to racemic formoterol, as the (R,R)-enantiomer is primarily responsible for bronchodilatory activity, while the (S,S)-enantiomer has minimal activity. Additionally, Arformoterol has been shown in laboratory studies to inhibit the release of inflammatory mediators such as histamine and leukotrienes from lung mast cells.

The recommended dose of Arformoterol nebuliser solution is one 15 mcg unit-dose ampoule administered twice daily (morning and evening) by nebulization. A total daily dose of greater than 30 mcg (15 mcg twice daily) is not recommended.

Pediatric Use: COPD does not occur in children. The safety and efficacy of Arformoterol nebuliser solution in pediatric patients have not been established

Arformoterol Tartrate may have enhanced effects when used with other adrenergic agents. Concomitant use with xanthine derivatives, corticosteroids, or diuretics (especially non–potassium-sparing diuretics) may increase the risk of hypokalemia and ECG abnormalities. Monoamine oxidase (MAO) inhibitors, tricyclic antidepressants, and drugs that prolong the QT interval may increase cardiovascular effects. Beta-blockers may reduce the bronchodilatory effectiveness of Arformoterol.

Common side effects include pain, chest discomfort, back pain, diarrhea, sinusitis, leg cramps, shortness of breath, rash, flu-like symptoms, peripheral edema, and lung-related disorders. Serious adverse effects may include an increased risk of asthma-related death in patients using LABA medications. Immediate medical attention is required if breathing worsens rapidly or if rescue inhalers fail to relieve symptoms.

Pregnancy Category C. Arformoterol should be used during pregnancy only if the potential benefit justifies the possible risk to the fetus. It is not known whether the drug is excreted in human breast milk.

Arformoterol should not be initiated in patients with acute worsening of respiratory symptoms. Use cautiously in patients with cardiovascular disease, seizure disorders, thyrotoxicosis, or hypersensitivity to sympathomimetic drugs. Paradoxical bronchospasm, which may be life-threatening, can occur in some patients.

Overdose of Arformoterol may lead to serious cardiovascular complications, including cardiac arrest and potentially fatal outcomes, similar to other inhaled sympathomimetic agents.

Long-acting bronchodilator (LABA).

Store at 2–8°C, protected from light and excessive heat. Do not freeze. Keep out of reach of children.